River Wealth Advisors LLC Boosts Stock Holdings in Eli Lilly and Company $LLY

River Wealth Advisors LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 10.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,316 shares of the company’s stock after acquiring an additional 1,213 shares during the period. Eli Lilly and Company makes up 1.1% of River Wealth Advisors LLC’s portfolio, making the stock its 24th largest holding. River Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $9,397,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the stock. Exencial Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after acquiring an additional 11,396 shares during the last quarter. Rede Wealth LLC bought a new stake in Eli Lilly and Company in the third quarter worth $487,000. Central Pacific Bank Trust Division raised its stake in Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after purchasing an additional 1,843 shares in the last quarter. Cidel Asset Management Inc. raised its stake in Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after purchasing an additional 5,591 shares in the last quarter. Finally, Oak Family Advisors LLC bought a new position in Eli Lilly and Company during the third quarter valued at $1,979,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Topline ACHIEVE‑3 results for type 2 diabetes showed meaningful A1C and weight benefits for Lilly’s oral GLP‑1 in a head‑to‑head setting, reinforcing the drug’s commercial and regulatory potential. Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes
• Positive Sentiment: Detailed Phase 3/Lancet results show orforglipron outperformed oral semaglutide on A1C and weight in ACHIEVE‑3, strengthening Lilly’s case for market share and supporting upcoming regulatory timelines (U.S. obesity decision possible in Q2). Orforglipron Lancet results PR Newswire
• Positive Sentiment: CHMP issued a positive opinion for expanded EU use of Olumiant (baricitinib) in adolescents with severe alopecia areata — a near‑term regulatory win that expands labeled indications and revenue opportunities in Europe. Olumiant CHMP positive opinion PR Newswire
• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $1,250 PT, signaling institutional confidence in Lilly’s obesity leadership; coupled with recent price‑target increases from other shops, this boosts investor conviction. RBC Capital initiates Eli Lilly
• Positive Sentiment: High‑profile media/TV endorsements (e.g., Jim Cramer recommending Lilly over Novo Nordisk) are supportive for retail flows and sentiment toward LLY. Jim Cramer Recommends Eli Lilly
• Neutral Sentiment: Reuters published additional trial safety data giving a more detailed picture of side effects — useful context for regulators and investors but not a clear negative or positive on balance. Reuters: additional data on weight-loss pill
• Neutral Sentiment: Health‑care stocks broadly moved higher today, which can amplify sector leaders’ moves but may reflect macro/flow dynamics rather than company‑specific fundamentals. Sector Update: Health Care Stocks Higher
• Negative Sentiment: Smaller rivals (e.g., Viking Therapeutics) and other entrants remain active in the obesity space — a potential long‑term competitive risk that could pressure pricing and market share over time. Viking Therapeutics profile

Analyst Ratings Changes

A number of research firms have recently weighed in on LLY. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Argus boosted their price objective on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Finally, Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,229.59.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,050.39 on Friday. The company has a 50 day moving average price of $1,053.15 and a 200-day moving average price of $930.04. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a market capitalization of $990.90 billion, a PE ratio of 45.77, a P/E/G ratio of 1.22 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period last year, the business posted $5.32 EPS. Eli Lilly and Company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.